Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) January 25, 2008
BioScrip, Inc.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 0-28740 | 05-0489664 | ||
| (State or Other Jurisdiction of | (Commission | (IRS Employer | ||
| Incorporation) | File Number) | Identification No.) |
| 100 Clearbrook Road, Elmsford, New York | 10523 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code (914) 460-1600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240-14d-2(b)).
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)).
TABLE OF CONTENTS
Table of Contents
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Transfer of Listing.
On January 24, 2008, BioScrip, Inc. (the “Company”) received written notification from the
Nasdaq Listing Qualifications Department (“Nasdaq”) that the Company had violated the shareholder
approval requirement set forth in Nasdaq Marketplace Rule 4350(i); the letter also indicated that the
Nasdaq staff had determined that the Company has regained compliance with the Rule and the matter
is now closed. The Company violated the above-referenced Rule by delivering to its non-employee
directors in May 2007 option agreements for an aggregate of 55,000 shares of Company common stock
under a director stock option plan that had expired prior to that date. The Company had previously
notified Nasdaq that the option agreements had been erroneously delivered, that the options
purportedly evidenced by the option agreements were never granted and that, upon discovery of the
error, the Company had cancelled the option agreements.
The Nasdaq letter also requires that the Company issue a press release disclosing receipt of
such letter and the Nasdaq rules upon which such letter was based. The Company issued such a press
release on January 25, 2008. A copy of the press release, dated January 25, 2008, is attached as
Exhibit 99.1 to this report. The exhibit is incorporated by reference into this Item 3.01.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description | |
99.1
|
Press Release, dated January 25, 2008. |
2
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned duly authorized.
| Date: January 25, 2008 | BIOSCRIP, INC. |
|||
| By: | /s/ Barry A. Posner | |||
| Barry A. Posner, | ||||
| Executive Vice President, Secretary and General Counsel | ||||
Table of Contents
Exhibit 99.1
[COMPANY LOGO]
FOR IMMEDIATE RELEASE
Elmsford, NY — January 25, 2008 — BioScrip, Inc. (NASDAQ:BIOS), a comprehensive
pharmaceutical care solutions company, today announced that on January 24, 2008, it received
written notification from the Nasdaq Listing Qualifications Department (“Nasdaq”) that it had
violated the shareholder approval requirement set forth in Nasdaq Marketplace Rule 4350(i); the
notice also indicated that the Nasdaq staff had determined that the Company has regained compliance with
the Rule and, with the issuance of this press release the matter is now closed. The Company violated the above-referenced Rule by
delivering to its non-employee directors in May 2007 option agreements for an aggregate of 55,000
shares of Company common stock under a director stock option plan that had expired prior to that
date. The Company had previously notified Nasdaq that the option agreements had been erroneously
issued, that the options purportedly evidenced by the option agreements were never granted and
that, upon discovery of the error, the Company had cancelled the option agreements.
About BioScrip, Inc.
BioScrip, Inc. (www.bioscrip.com) (Nasdaq: BIOS) is a specialty pharmaceutical health
care organization that partners with patients, physicians, health care payors and pharmaceutical
manufacturers to provide access to medications and management solutions to optimize outcomes for
chronic and other complex health care conditions.
Contact
Stanley G. Rosenbaum
Executive Vice President and
Chief Financial Officer
BioScrip, Inc.
Tel: 952-979-3768
Email: srosenbaum@bioscrip.com
Executive Vice President and
Chief Financial Officer
BioScrip, Inc.
Tel: 952-979-3768
Email: srosenbaum@bioscrip.com